Assembly Biosciences (NASDAQ:ASMB) Announces Earnings Results, Misses Estimates By $0.27 EPS

Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.27), FiscalAI reports. The company had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $9.07 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%.

Assembly Biosciences Stock Down 9.8%

NASDAQ:ASMB opened at $20.18 on Friday. The business’s 50-day simple moving average is $23.55 and its two-hundred day simple moving average is $26.87. Assembly Biosciences has a 52 week low of $19.20 and a 52 week high of $39.71. The stock has a market cap of $410.86 million, a PE ratio of 21.93 and a beta of 1.26.

Analysts Set New Price Targets

Several research analysts have recently commented on ASMB shares. UBS Group decreased their price objective on Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. Zacks Research lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research note on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Assembly Biosciences has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Insider Transactions at Assembly Biosciences

In related news, insider Nicole S. White sold 2,593 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $50,874.66. Following the completion of the sale, the insider owned 59,257 shares in the company, valued at approximately $1,162,622.34. This trade represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Anuj Gaggar sold 2,593 shares of Assembly Biosciences stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $50,874.66. Following the sale, the insider directly owned 53,800 shares in the company, valued at $1,055,556. This trade represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 12,115 shares of company stock valued at $237,696 over the last 90 days. Company insiders own 3.50% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.